Karl Keegan. Picture: Nox Therapeutics

Hox Therapeutics appoints Karl Keegan as CEO

Hox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.

Dr Karl Keegan has over 25 years’ experience in the biotech/pharma sector. Following his MPhil/PhD degrees at Cambridge, he did postdoctoral work at Baylor College of Medicine, Texas before moving to industry. From 2009, he has held key executive positions including CFO/corporate development roles at Pharming Group NV, Vectura Group Plc and Shield Therapeutics Plc.

James Culverwell, Chairman of Hox Therapeutics, said: “We are very pleased to welcome Karl at this critical stage in the Company’s development.  As we are preparing to move into phase I proof-of-concept studies with our lead product, we are expanding the executive leadership team with experts in clinical oncology and operations, regulatory affairs and manufacturing as HOX transitions to be a clinical-stage biotech company.”